Elan To Relaunch Naprelan In October; Searle Sells OC Line To Watson
Executive Summary
Elan will be relaunching the non-steroidal anti-inflammatory drug Naprelan in October, the company said following its reacquisition of the product from Wyeth-Ayerst.